NEW YORK — Takeda Pharmaceutical has completed its acquisition of Shire, 8 months after the deal was announced, according to a press release. The deal was approved by 89.1% of Takeda’s shareholders and 99.8% of Shire’s shareholders, the release said. “We are delighted that the acquisition was approved by an overwhelming majority of our shareholders
LEXINGTON, Mass. — Shire plc has received Food and Drug Administration approval for Xiidra 5% (lifitegrast ophthalmic solution), a twice-daily eye drop solution for dry eye. Plans call for Xiidra to launch in the United States in the third quarter. Shire said the product represents the only prescription eye drop indicated for the treatment of
DUBLIN, Ireland, and BANNOCKBURN, Ill. — Shire plc plans to buy Baxalta Inc., a biopharmaceutical company focused on orphan diseases and underserved conditions, in a cash and stock deal valued at $32 billion. Under the agreement, Baxalta shareholders will receive $18 in cash and 0.1482 Shire American depositary shares per Baxalta share, for a combined of
